Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLF10 | Q13118 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
| ▸ | VDR | P11473 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 7/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | SHBG | P04278 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25767568 | 0.83 | ESR1 (0.33) | SCN10ABRAFCYP2C9ESR1ESR2 | |
| SCHEMBL10211670 | 0.80 | KLF10 (0.50) | KLF10S1PR1VDRESR1SHBG | |
| SCHEMBL10227953 | 0.79 | SCN10A (0.38) | SCN10ABRAFCYP2C9ESR1GRM1 | |
| SCHEMBL17224473 | 0.79 | CASP1 (0.42) | KLF10 | |
| SCHEMBL25767593 | 0.78 | CNR1 (0.31) | SCN10AESR1CNR1ESR2 | |
| SCHEMBL18560993 | 0.74 | RORC (0.32) | BRAFESR1ESR2RORC | |
| SCHEMBL15062087 | 0.74 | S1PR1 (0.51) | KLF10S1PR1VDRSHBG | |
| SCHEMBL8855639 | 0.74 | BRAF (0.36) | SCN10ABRAFCYP2C9ESR1GRM1 | |
| SCHEMBL307936 | 0.74 | SCN10A (0.36) | SCN10ABRAFESR1CNR1ESR2 | |
| SCHEMBL30558289 | 0.73 | BRAF (0.35) | SCN10ABRAFCYP2C9ESR1GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9902730-B2 | Compounds and compositions as toll-like receptor 7 agonists | NOVARTIS AG (CH) | 2018-02-27 | — | — | US | disclosed |
| US-20170057968-A1 | COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS | NOVARTIS AG (CH) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057968-A1 | COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS | TLR7, TLR3, TLR1 | KLF10 2124/4885S1PR1 744/4885SCN10A 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.